PAP
CBIO

Persistent Asset Partners’s Crescent Biopharma CBIO Stock Holding History

Persistent Asset Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
+10,968
New +$214K 0.06% 218

Other funds holding CBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $429M AUM 52.52% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Persistent Asset Partners's CBIO Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 10,968 shares worth $197K. The stake represents 0.06% of the portfolio and ranks #218 among its holdings.

23 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Persistent Asset Partners held 10,968 shares of Crescent Biopharma worth $197K as of Q2 2026.
  • Crescent Biopharma was a new Persistent Asset Partners position in Q2 2026.
  • Crescent Biopharma made up 0.06% of Persistent Asset Partners's portfolio in Q2 2026, its #218 holding.
  • 23 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.